Muricholic Acid Species Regulation Networks: From Biosynthetic Pathways to Molecular Mechanisms
Year: 2026
Type: article
Abstract: Bile acids (BAs) are pleiotropic signaling molecules. Muricholic acids (MCAs), a distinct BA subgroup with hydroxyl groups at C3, C6, and/or C7, exhibit structural diversity that underpins functional heterogeneity. This review summarizes MCA species and their derivatives, emphasizing metabolic pathway differences between rodents and humans. We explore gut microbiota-mediated MCA transformation and the associated regulatory networks. MCAs modulate key signaling receptors—farnesoid X receptor (FXR), Takeda G protein-coupled receptor 5 (TGR5), and peroxisome proliferator-activated receptor α (PPARα)—as well as pathways including the gut–liver axis, ceramide metabolism, cyclic guanosine monophosphate–protein kinase G–mechanistic target of rapamycin complex 1 (cGMP–PKG–mTORC1) signaling, and the hypothalamic–pituitary–gonadal (HPG) axis. These actions implicate MCAs in metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes mellitus (T2DM), inflammatory bowel disease (IBD), central precocious puberty (CPP). Their potential as diagnostic, predictive, and prognostic biomarkers is also discussed. This synthesis provides a theoretical foundation for understanding MCA-driven disease mechanisms and developing novel therapeutic strategies.
Authors: Guangzeng Zhou, Lihui Wei, Mai Han, Rong Rong, Yan Ni
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: muricholic acids, bile acids, bile acid synthesis, gut microbiota, farnesoid X receptor, TGR5, PPARα, gut-liver axis, ceramide metabolism, hypothalamic-pituitary-gonadal axis, non-alcoholic fatty liver disease, type 2 diabetes, inflammatory bowel disease, central precocious puberty, biomarkers
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7236629441
